Regarding drug metabolism and hepatotoxicity, sorafenib, as a first-line targeted therapy for liver cancer, has its efficacy and toxicity heavily dependent on the metabolic activity of cytochrome P450 (CYP3A4) (92). The gene discussed is CYP3A4; the disease is liver cancer.